Immunosuppression and Epstein-Barr virus (EBV) have been linked to the development of post-transplant lymphoproliferative disease.' It is thought to arise from abnormal B cell proliferation prompted by EBV infection and unchecked because of selective T cell suppression by cyclosporin.2 The early diagnosis of posttransplant lymphoproliferative disease is important as the prompt institution of treatment may arrest the evolution of a simple EBV induced polyclonal B cell proliferation to a monoclonal B cell lymphoma. 3 We report two heart-lung transplant recipients with a normal chest radiograph in whom the presence of an ulcerative bronchitis observed at fibreoptic bronchoscopy was an early clinical marker for post-transplant lymphoproliferative disease.
Case 1 A 45 year old woman underwent heart-lung transplantation for emphysema due to oc,-antitrypsin deficiency. She received induction immunosuppression of methylprednisolone, 1 g, azathioprine, 4 mg/kg before the transplant, and rabbit antithymocyte globulin, 1 mg/kg daily for three days, followed by maintenance immunosuppression of cyclosporin, oral prednisolone, and azathioprine. infiltration by high grade non-Hodgkin's lymphoma which were largely necrotic. Tumour cells were seen invading bronchi, blood vessels, and air spaces. The mediastinal nodes also showed necrotic lymphoma but no tumour was found in extrathoracic sites. Invasive aspergillosis was also present in the lung with infarctlike areas ofnecrosis and sloughing ofbronchial epithelium. Like other published series ofpost-transplant lymphoproliferative disease in heart-lung transplant recipients a common characteristic in our cases was the early presentation within the graft (four months) following transplantation. The reason for this remains unclear but, as prospective donor/recipient HIA matching does not occur, it is possible that chronic antigenic stimulation due to rejection in conjunction with latent EBV genome in the graft BALT results in the post-transplant lymphoproliferative disease evolving rapidly. The chronic antigenic stimulation which occurs with repeated malarial infections is considered to be an important adjunct to EBV in the development of Burkitt's lymphoma.'
Bronchial changes have been documented in the presence of pathogenic organisms such as Aspergillus.9 In case 1 the presence of Pseudomonas aeruginosa annd Aspergillus resulted in therapeutic trials which delayed the diagnosis of post-transplant lymphoproliferative disease.
In the clinical/pathological spectrum of posttransplant lymphoproliferative disease a benign lymphoid proliferative response to EBV may respond to a reduction in immunotherapy and antiviral agents. Early intervention in posttransplant lymphoproliferative disease may therefore prevent the progression of the disease since ganciclovir has been shown to inhibit the development of B cell lymphoma in an immunocompromised mouse model.'" Ulcerative bronchitis in a heart-lung transplant recipient may be the first sign of posttransplant lymphoproliferative disease, and suggests that BALT in the grafted lung is an important site for the initiation of clonal B cell proliferation in post-transplant lymphoproliferative disease.
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